Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Establishment of the Initial Protocol With Intravitreal Bevacizumab for the Treatment of Choroidal Neovascularization Associated With High Myopia:3 vs 1.

Next Previous
Search
Trial Profile

Establishment of the Initial Protocol With Intravitreal Bevacizumab for the Treatment of Choroidal Neovascularization Associated With High Myopia:3 vs 1.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Myopia
  • Focus Therapeutic Use
  • Acronyms BENEMCOR

Most Recent Events

  • 10 Mar 2023 Status changed from active, no longer recruiting to completed.
  • 27 Mar 2017 Planned End Date changed from 1 Jan 2016 to 1 Dec 2017.
  • 27 Mar 2017 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top